globotriaosylceramide and Renal-Insufficiency

globotriaosylceramide has been researched along with Renal-Insufficiency* in 3 studies

Reviews

1 review(s) available for globotriaosylceramide and Renal-Insufficiency

ArticleYear
Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.
    Molecular genetics and metabolism, 2012, Volume: 107, Issue:3

    Anderson-Fabry disease is an X-linked lysosomal storage disorder resulting from the deficiency of the hydrolytic enzyme alpha galactosidase A, with consequent accumulation of globotrioasoyl ceramide in cells and tissues of the body, resulting in a multi-system pathology including end organ failure. In the classical phenotype, cardiac failure, renal failure and stroke result in a reduced median life expectancy. The current causal treatment for Fabry disease is the enzyme replacement therapy (ERT): two different products, Replagal (agalsidase alfa) and Fabrazyme (agalsidase beta), have been commercially available in Europe for almost 10 years and they are both indicated for long-term treatment. In fact, clinical trials, observational studies and registry data have provided many evidences for safety and efficacy of ERT in improving symptoms of pain, gastrointestinal disturbances, hypohidrosis, left ventricular mass index, glomerular filtration rate and quality of life. Few data are available on comparison of the two treatments and on the clinical course of the disease. This article reviews the published evidence for clinical efficacy of the two available enzyme preparations.

    Topics: Adult; alpha-Galactosidase; Clinical Trials as Topic; Enzyme Replacement Therapy; Fabry Disease; Female; Galactosidases; Heart Failure; Humans; Isoenzymes; Male; Recombinant Proteins; Renal Insufficiency; Stroke; Trihexosylceramides

2012

Other Studies

2 other study(ies) available for globotriaosylceramide and Renal-Insufficiency

ArticleYear
Risk of haemolytic uraemic syndrome caused by shiga-toxin-producing Escherichia coli infection in adult women in Japan.
    Epidemiology and infection, 2016, Volume: 144, Issue:5

    Shiga-toxin-producing Escherichia coli (STEC) infections usually cause haemolytic uraemic syndrome (HUS) equally in male and female children. This study investigated the localization of globotriaosylceramide (Gb3) in human brain and kidney tissues removed from forensic autopsy cases in Japan. A fatal case was used as a positive control in an outbreak of diarrhoeal disease caused by STEC O157:H7 in a kindergarten in Urawa in 1990. Positive immunodetection of Gb3 was significantly more frequent in female than in male distal and collecting renal tubules. To correlate this finding with a clinical outcome, a retrospective analysis of the predictors of renal failure in the 162 patients of two outbreaks in Japan was performed: one in Tochigi in 2002 and the other in Kagawa Prefecture in 2005. This study concludes renal failure, including HUS, was significantly associated with female sex, and the odds ratio was 4ยท06 compared to male patients in the two outbreaks. From 2006 to 2009 in Japan, the risk factor of HUS associated with STEC infection was analysed. The number of males and females and the proportion of females who developed HUS were calculated by age and year from 2006 to 2009. In 2006, 2007 and 2009 in adults aged >20 years, adult women were significantly more at risk of developing HUS in Japan.

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Brain; Child; Child, Preschool; Diarrhea; Disease Outbreaks; Escherichia coli Infections; Female; Hemolytic-Uremic Syndrome; Humans; Infant; Infant, Newborn; Japan; Kidney; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Risk Factors; Sex Factors; Shiga-Toxigenic Escherichia coli; Trihexosylceramides; Young Adult

2016
Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.
    Kidney international, 2011, Volume: 79, Issue:6

    Progressive renal failure often complicates Fabry disease, the pathogenesis of which is not well understood. To further explore this we applied unbiased stereological quantitative methods to electron microscopic changes of Fabry nephropathy and the relationship between parameters of glomerular structure and renal function in 14 young Fabry patients (median age 12 years). Renal biopsies were obtained shortly before enzyme replacement therapy from these patients and from nine normal living kidney donors as controls. Podocyte globotriaosylceramide (GL-3) inclusion volume density increased progressively with age; however, there were no significant relationships between age and endothelial or mesangial inclusion volume densities. Foot process width, greater in male Fabry patients, also progressively increased with age compared with the controls, and correlated directly with proteinuria. In comparison to the biopsies of the controls, endothelial fenestration was reduced in Fabry patients. Thus, our study found relationships between quantitative parameters of glomerular structure in Fabry nephropathy and age, as well as urinary protein excretion. Hence, podocyte injury may play a pivotal role in the development and progression of Fabry nephropathy.

    Topics: Adolescent; Age Factors; Biomarkers; Biopsy; Case-Control Studies; Child; Child, Preschool; Creatinine; Disease Progression; Endothelial Cells; Europe; Fabry Disease; Female; Glomerular Filtration Rate; Humans; Kidney Glomerulus; Least-Squares Analysis; Linear Models; Male; Podocytes; Proteinuria; Renal Insufficiency; Risk Assessment; Risk Factors; Sex Factors; Trihexosylceramides; United States; Up-Regulation; Young Adult

2011